OptiNose, Inc.
http://www.optinose.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptiNose, Inc.
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m
Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
- Other Names / Subsidiaries
-
- OptiNose AS
- OptiNose UK Ltd.
- OptiNose US, Inc.